Open AccessBiologic Therapy of Moderate and Severe Forms of Atopic Dermatitis in Children
Author(s) -
Н. Н. Мурашкин,
Л. С. Намазова-Баранова,
Л. А. Опрятин,
Р. В. Епишев,
А. И. Материкин,
Э. Т. Амбарчян,
Р. А. Иванов,
Д. В. Фёдоров,
Д. С. Куколева
Publication year - 2020
Publication title -
voprosy sovremennoj pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.12
H-Index - 5
eISSN - 1682-5535
pISSN - 1682-5527
DOI - 10.15690/vsp.v19i6.2145
Subject(s) - dupilumab , atopic dermatitis , medicine , disease , dysbiosis , immunology , microbiome , dermatology , inflammation , pathogenesis , population , psoriasis , pathology , bioinformatics , biology , environmental health
Atopic dermatitis (AD) is the disease with chronic inflammation, epidermal barrier dysfunction and microbial dysbiosis. AD is widespread, including pediatric population. The article discusses the disease’s pathogenesis: skin barrier deficiency, immunological causes of chronic inflammation, characteristics of normal skin microbiome and its disorders on both affected and unaffected skin of children with AD. Main principles of systemic treatment for moderate and severe forms of disease are considered. Features of targeted therapy with dupilumab (IL 4/IL 13 inhibitor) in children with moderate and severe forms of AD are discussed. The overview of the research results on the dupilumab efficacy and safety is presented.